TFX 8-K SEC Filing Analysis

Latest settled — T+5d

TFX ▲ +1.98% at T+5d

NEUTRAL call ✓ call won +1.98% · α vs SPY +4.73% · entry $127.31 → $129.84

Next anchor: T+20d in 15d

Last close $130.48 (close Jun 12) · +2.49% from $127.31 entry

Entry anchored
May 29, 03:59 PM ET
via Databento tick

T+1d

-1.75%

call -1.75% · α -1.90%

$125.08

settled 13d ago

T+5d

+1.98%

call +1.98% · α +4.73%

$129.84

settled 7d ago

T+20d

—

call — · α —

—

in 15d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Teleflex announced a private offering of $500 million in senior notes due 2032, with proceeds to redeem all outstanding 4.625% senior notes due 2027. The filing also includes unaudited Adjusted EBITDA and capitalization metrics. This refinancing extends debt maturities and reduces near-term refinancing risk, without materially altering leverage.

Actionable Insight

The refinancing is credit-neutral, extending maturities without increasing leverage significantly. Monitor the final interest rate on the new notes and any updates on the $1.0B share repurchase program. The weak free cash flow in 2025 warrants attention, but strategic divestitures may improve the financial profile.

Key Facts

Private offering of $500M senior notes due 2032, interest rate to be determined at pricing.
Proceeds from offering, plus cash on hand, will redeem all $500M of 4.625% senior notes due 2027.
Adjusted EBITDA (continuing ops) for FY2025: $530.9M; trailing twelve months ended March 31, 2026: $536.6M.
Total indebtedness as adjusted after offering: $2.825B vs actual $2.625B at March 31, 2026.
Share repurchase program of $1.0B authorized, with $200M already repurchased via borrowings.
Free cash flow from continuing ops for FY2025 was only $1.4M.

Financial Impact

Debt refinancing of $500M; no net change in principal amount, but extension of maturity from 2027 to 2032. Total debt increases by $200M on an as-adjusted basis due to additional borrowings for share repurchases.

debt maturity profileinterest expensetotal indebtedness

Risk Factors

Interest rate on new notes may be higher than the 4.625% coupon being redeemed, increasing interest expense.
Borrowings for share repurchases increase leverage and reduce financial flexibility.
Strategic divestitures may not close as expected, impacting deleveraging plans.

Market Snapshot

Exchange

NYSE

Sector

Surgical & Medical Instruments & Apparatus

Analyst Consensus

29% bullish (17 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-249764
Document: d126202d8k.htm	0001193125-26-249764
Document: d126202dex991.htm	0001193125-26-249764
Document: 0001193125-26-249764-index-headers.html	0001193125-26-249764
Document: 0001193125-26-249764-index.html	0001193125-26-249764
Document: 0001193125-26-249764.txt	0001193125-26-249764

5 reports for TFX

T+1T+5T+20T+60

Filters

Reports for TFX — sortable, filterable
	Type				Now
Jun 9, 2026 5d ago	8-K NEUTRAL ★ 2/10	$135.61 awaiting T+5	awaiting T+5	—	$130.48 (−3.78%)
Jun 1, 2026 13d ago	8-K NEUTRAL ★ 4/10	$127.31 $129.84	▲ +1.98%	▲ +4.73%	$130.48 (+2.49%)
May 27, 2026 18d ago	8-K NEUTRAL ★ 4/10	$128.90 $131.04	▲ +1.66%	▲ +1.34%	$130.48 (+1.22%)
May 7, 2026 5w ago	8-K MIXED ★ 6/10	$131.59 $130.04	▼ −1.18%	▼ −2.69%	$130.48 (−0.85%)
Feb 26, 2026 15w ago	8-K MIXED ★ 7/10	$118.39 $116.75	▼ −1.39%	▼ −0.26%	$130.48 (+10.21%)

US Market Status

Market Closed — Opens in 4h 44m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access